CORT Financial Facts

Loss from operations: 592K
Basic and diluted net loss per share: 0
See Full Income Statement

Accounts payable: 2.08M
Total stockholders' equity: 20.17M
See Full Balance Sheet

Corcept Therapeutics (CORT) Earnings

  |   Expand Research on CORT
Next EPS Date 8/5/16 *Est. EPS Growth Rate +140.0% *Last Qtr.
Average EPS % Beat Rate +87.5% Revenue Growth Rate +59.4% *Last Qtr.
Average % Move 1-Wk after EPS +9.9% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/3/16 Q116 $0.02$0.01 +$0.01$16.1M$16.32M = Details
1/28/16 Q415 $0.01-$0.02 +$0.03$15M$15.5M = Details
11/5/15 Q315 -$0.01-$0.02 +$0.01$13.3M$13.9M N/A Details
8/5/15 Q215 -$0.02-$0.04 +$0.02$12M$11.67M N/A Details
5/7/15 Q115 -$0.05-$0.04 -$0.01$10.1M$10.5M N/A Details
3/4/15 Q414 -$0.02-$0.06 +$0.04$9.01M$9.1M N/A Details
11/4/14 Q214 N/A-$0.07 N/A N/A$7.62M N/A N/A N/A
5/7/14 Q114 -$0.11-$0.09 -$0.02$4.41M$5.01M N/A Details